Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02668991 · ClinicalTrials.gov registry record

Study to Assess the Janssen Autism Knowledge Engine in Participants With Autism Spectrum Disorder and in a Normally Developing Cohort

A clinical trial of Autism Spectrum Disorder, sponsored by Janssen Research & Development.

Completed
Registry status
186
Enrollment target
9
Study locations

NCT02668991: Completed study of Autism Spectrum Disorder, sponsored by Janssen Research & Development.

NCT02668991 is a study of Autism Spectrum Disorder that has completed, run by Janssen Research & Development. The registered enrollment target is 186 participants, above the 134-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (39% higher). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02668991, a study of Autism Spectrum Disorder, has completed, sponsored by Janssen Research & Development.

COMPLETED
Registry status
186 participants
Enrollment target
9
Study locations

Study Summary

The purpose of this study is to evaluate the utility of and to clinically validate the Autism Behavior Inventory (ABI) in measuring clinical symptoms of Autism Spectrum Disorder (ASD) compared with other gold standard measures.

Primary Outcome

The ABI is a series of 73 questions related to the core and associated symptoms of ASD. Questions are answered on two 4-point scales, consisting of ratings of frequency and intensity, frequency and context, or quality and context.

Conditions Studied

Study Locations (9)

Arizona

  • - Phoenix

California

  • - San Francisco

Connecticut

  • - New Haven

Massachusetts

  • - Worcester

New Jersey

  • - Toms River

New York

  • - Orangeburg

North Carolina

  • - Durham

Pennsylvania

  • - Philadelphia

Trial Details

FieldValue
Enrollment Target 186 participants
Start Date 2015-07
Est. Completion 2016-10
Janssen Research & Development

593 total trials

What the finished NCT02668991 record still lists

NCT02668991 is an observational study that tracks outcomes without assigning an intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, above the 134-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (39% higher).

The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 0 interventions.

NCT02668991 lists 9 locations in 9 states (Arizona, California, Connecticut).

Frequently Asked Questions

What is clinical trial NCT02668991 about?

NCT02668991 is a clinical study titled "Study to Assess the Janssen Autism Knowledge Engine in Participants With Autism Spectrum Disorder and in a Normally Developing Cohort". The purpose of this study is to evaluate the utility of and to clinically validate the Autism Behavior Inventory (ABI) in measuring clinical symptoms of Autism Spectrum Disorder (ASD) compared with other gold standard measures.

What is the current status of trial NCT02668991?

This trial is currently completed. The enrollment target is 186 participants. The study started on 2015-07. Estimated completion is 2016-10.

What conditions does trial NCT02668991 study?

This clinical trial studies the following conditions: Autism Spectrum Disorder.

Who is sponsoring clinical trial NCT02668991?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02668991 being conducted?

This trial has 9 study locations across Arizona, California, Connecticut, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autism Spectrum Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02668991's enrollment target sits among peer trials

186 45th of 224 higher than 180 of 224 other Autism Spectrum Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03567889 · 186 participants · Phase 3

    Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

  • NCT05281471 · 186 participants · Phase 3

    Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

  • NCT05405595 · 186 participants · Phase 1

    ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

  • NCT05762107 · 186 participants · Phase 2

    A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02668991, the US trial registry maintained by the National Library of Medicine. NCT02668991 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.